Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MIF-I and postsynaptic receptor sites for dopamine.

R M Kostrzewa, J C Hardin, R L Snell

    Brain Research Bulletin
    |September 1, 1979
    PubMed
    Summary

    The antiparkinsonian peptide l-prolyl-l-leucyl-glycine amide (PLG, MIF-I) does not directly affect striatal dopamine receptors or key enzyme activities. Further research is needed to understand its indirect mechanisms in vivo.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Measurement of efflux rates from brain to blood.

    Methods in molecular biology (Clifton, N.J.)·1997
    Same author

    Aluminum-sensitive degradation of amyloid beta-protein 1-40 by murine and human intracellular enzymes.

    Neurotoxicology and teratology·1996
    Same author

    Perinatal treatment of rats with opiates affects the development of the blood-brain barrier transport system PTS-1.

    Neurotoxicology and teratology·1996
    Same author

    Differential permeability of the BBB in acute EAE: enhanced transport of TNT-alpha.

    The American journal of physiology·1996
    Same author

    Sequestration of centrally administered insulin by the brain: effects of starvation, aluminum, and TNF-alpha.

    Hormones and behavior·1996
    Same author

    Binding of Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH2) and related peptides to mu 1 and mu 2 opiate receptors.

    Neuroscience letters·1996

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Biochemistry

    Background:

    • Parkinson's disease is a neurodegenerative disorder affecting motor control.
    • The tripeptide l-prolyl-l-leucyl-glycine amide (PLG, MIF-I) shows antiparkinsonian effects.
    • The precise mechanism of action for PLG remains unclear.

    Purpose of the Study:

    • To investigate the direct postsynaptic mechanisms of PLG's antiparkinsonian effect.
    • To assess PLG's impact on key enzymes and dopamine receptor interactions in the striatum.

    Main Methods:

    • Enzyme activity assays for tyrosine hydroxylase, dopa decarboxylase, choline acetyltransferase, and glutamic acid decarboxylase.
    • In vitro enzyme activity tests for adenylate cyclase and guanylate cyclase with varying PLG concentrations.

    Related Experiment Videos

  • Measurement of 3H-dopamine uptake in striatal synaptosomes.
  • Radioligand binding assays for 3H-dopamine and 3H-spiperone.

    • Main Results:

    • PLG administration did not alter the activity of key enzymes in rat striatum.
    • PLG did not affect adenylate cyclase or guanylate cyclase activity in vitro.
    • Striatal synaptosome dopamine uptake and dopamine/spiperone binding to membranes were unchanged by PLG.

    Conclusions:

    • PLG does not appear to act directly on striatal dopaminergic postsynaptic components.
    • PLG's antiparkinsonian effects may be mediated through indirect mechanisms in vivo.
    • Further studies are warranted to elucidate potential indirect pathways of PLG action.